Death or BPD (28 days) · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in death or BPD at 28 days compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · Neonates with developing BPD
Inhaled steroids showed no clear difference in death or BPD at 36 weeks' postmenstrual age compared with systemic steroids (moderate certainty).
2 findings from 1 review
Foetal death · pregnant women
It is very uncertain whether topical corticosteroids changes foetal death compared with no topical corticosteroids (very low certainty).
1 finding from 1 review
RR 1.02
63885 participants
Very low
Death or moderate/severe disability at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in death or moderate/severe disability at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
BPD or death at 36 weeks' postmenstrual age№ of participants: 0 (0 RCTs) · preterm infants with respiratory distress for initial respiratory support
Inhaled steroids showed no clear difference in death or BPD at 36 weeks' postmenstrual age among all randomised compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
Foetal death · pregnant women
Mild/moderate topical corticosteroids may leads to lower foetal death compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.7
48749 participants
Low
Foetal death · pregnant women
Potent/very potent topical corticosteroids may leads to higher foetal death compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.14
37086 participants
Low
Death at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids showed no clear difference in death at final compared with placebo/no treatment/steroids (low certainty).
1 finding from 1 review
Death at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes death at final compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
Death at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes death at final compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review
Adverse events: death · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: death compared with oral steroids alone (low certainty).
1 finding from 1 review
Maternal death · women at risk of preterm birth
Maternal outcomes: corticosteroids showed no clear difference in maternal death compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
RR 1.19 [0.36, 3.89]
Studies not reported
Moderate
Death at 1 month (adults) · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids leads to lower death at 1 month (adults) compared with no such treatment (high certainty).
1 finding from 1 review
Death in hospital; children · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids showed no clear difference in death in hospital; children compared with no such treatment (moderate certainty).
1 finding from 1 review
Death at 3 to 4 months (adults) · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids leads to lower death at 3 to 4 months (adults) compared with no such treatment (high certainty).
1 finding from 1 review
Perinatal mortality · Pregnant women with hyperemesis gravidarum
Corticosteroids showed no clear difference in stillbirth and neonatal death compared with promethazine (low certainty).
1 finding from 1 review
Perinatal mortality · Pregnant women with hyperemesis gravidarum
It is very uncertain whether corticosteroids changes stillbirth and neonatal death compared with placebo (very low certainty).
1 finding from 1 review
Mortality or serious adverse events requiring hospital admission · people with radicular low back pain (not due to spinal stenosis)
It is very uncertain whether systemic corticosteroids changes participants who experienced a serious adverse event Adverse event… compared with placebo (very low certainty).
1 finding from 1 review
Death ‐ at 180 days after ICU admission, in total population randomised · critically ill patients
Corticosteroids showed no clear difference in death ‐ death at 180 days in total population randomised compared with placebo compared (high certainty).
1 finding from 1 review
Admission to hospital or death · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care probably leads to lower admission to hospital or death compared with standard care (with or without placebo) (moderate certainty).
1 finding from 1 review